SCHEMBL7130530

SCHEMBL7130530

COC(=O)c1cccc(-c2cccs2)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KMT2A Q03164 5/20 0.46
MEN1 O00255 3/20 0.46
MAPT P10636 11/20 0.45
KDM4E B2RXH2 3/20 0.45
TSHR P16473 1/20 0.45
NPC1 O15118 1/20 0.45
HSD17B10 Q99714 2/20 0.44
RAB9A P51151 1/20 0.44
NR4A2 P43354 1/20 0.44
ALDH1A1 P00352 2/20 0.44
GAA P10253 2/20 0.44
USP2 O75604 1/20 0.44
ALOX15 P16050 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TP53 P04637 3/20 0.43
TDP1 Q9NUW8 3/20 0.42
THRB P10828 2/20 0.42
PTPRC P08575 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4249807 0.84 KMT2A (0.53) SLC6A4SLC6A3KMT2AMEN1MAPT
SCHEMBL22261511 0.84 ALDH1A1 (0.53) KMT2AMEN1MAPTKDM4ETSHR
SCHEMBL19923176 0.82 SLC6A3 (0.59) SLC6A4SLC6A3KMT2AMEN1MAPT
SCHEMBL13824013 0.82 MAPT (0.45) SLC6A4SLC6A3KMT2AMEN1MAPT
SCHEMBL7125127 0.81 DHODH (0.49) KMT2AMEN1MAPTKDM4ETSHR
SCHEMBL1610957 0.80 KMT2A (0.55) KMT2AMEN1MAPTKDM4ETSHR
SCHEMBL11271816 0.80 KMT2A (0.48) SLC6A4SLC6A3KMT2AMEN1MAPT
SCHEMBL22261509 0.79 KMT2A (0.43) SLC6A3KMT2AMEN1MAPTKDM4E
SCHEMBL12320666 0.78 KMT2A (0.53) KMT2AMEN1MAPTKDM4ETSHR
SCHEMBL21088415 0.78 SLC6A4 (0.49) SLC6A4SLC6A3KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 SLC6A4 962/4885SLC6A3 524/4885KMT2A 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.